small integral membrane protein 20Genealiases: C4orf52 · MITRAC7 · PNX
Q-omics provides the consensus-scored SMIM20 profile across patient tissues and cancer cell-line models. SMIM20 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SMIM20 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, SMIM20 RNA expression shows 18,715 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, THCA, and UVM as cancer lineages where SMIM20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM20 survival associations across molecular data types. SMIM20 RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM20 RNA expression–survival associations across cancer types. High SMIM20 expression shows unfavorable associations in LGG, SCLC, UVM, LIHC and GBM, but favorable associations in SKCM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SMIM20 RNA expression.
This table summarizes SMIM20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SMIM20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM20 shows lower tumor expression in THCA, BRCA, UCEC and KIRC and higher tumor expression in CHOL and LIHC. The THCA box plot shows higher SMIM20 RNA expression in normal versus tumor tissue (log2 FC = −0.362, t-test p < 0.001).
This table shows molecular features associated with SMIM20 in patient tissues and cancer cell lines. In patient samples, SMIM20 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
